中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.023 seconds)

    Purinone compounds as kinase inhibitors
    21.
    发明专利
    Purinone compounds as kinase inhibitors 未知

    公开(公告)号：AU2016206309A1

    公开(公告)日：2016-08-04

    申请号：AU2016206309

    申请日：2016-07-20

    Applicant: PHARMACYCLICS LLC

    Inventor： CHEN WEI ,  LOURY DAVID J ,  YAN SHUNQI ,  WANG LONGCHENG ,  FRYE LEAH LYNN

    IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00 ,  A61P37/00

    Abstract: Abstract Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
    22.
    发明专利
    DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK) 未知

    公开(公告)号：PE20160560A1

    公开(公告)日：2016-06-09

    申请号：PE2016000427

    申请日：2014-09-29

    Applicant: PHARMACYCLICS LLC

    Inventor： CHEN WEI ,  WANG LONGCHENG ,  LOURY DAVID J ,  JIA ZHAOZHONG J

    IPC: A61K31/519 ,  A61P19/00 ,  A61P19/02 ,  C07D401/14 ,  C07D403/14

    Abstract: La presente invencion se refiere a derivados de pirazolo[3,4-d]pirimidin de formula (I), en donde: L1 es –N(R2)C(O)- o –C(O)N(R2)-; R1 es arilo C6-C12, entre otros; R2 es H o alquilo C1-C4; R4 es H, alquilo C1-C6, entre otros; R5 es cicloalquilo C3-C8, entre otros; R10 es halogeno, entre otros; m es 1 o 2; n es 0 o 1 y p es 0, 1 o 2. Son compuestos preferidos: (R,E)-4-(4-amino-1-(1-(4-(ciclopropil(metil)amino)but-2-enoil)pirrolidin-3-il)- 1H-pirazolo[3,4-d]pirimidin-3-il)-N-(4-metilpiridin-2-il)benzamida; (R,E)-4-(4-amino-1-(1-(4-(ciclopropil(metil)amino)but-2-enoil)pirrolidin-3-il)- 1H-pirazolo[3,4-d]pirimidin-3-il)-N-(4-(trifluorometil)piridin-2-il)benzamida, entre otros. Estos derivados actuan como inhibidores irreversibles de la Tirosina Cinasa de Bruton (Btk) siendo utiles en el tratamiento de enfermedades autoinmunitarias, heteroinmunitarias, cancer, inclusive linfoma y enfermedades inflamatorias

    Inhibitors of Bruton's tyrosine kinase
    23.
    发明专利
    Inhibitors of Bruton's tyrosine kinase 未知

    公开(公告)号：AU2014324532A1

    公开(公告)日：2016-04-21

    申请号：AU2014324532

    申请日：2014-09-29

    Applicant: PHARMACYCLICS LLC

    Inventor： WANG LONGCHENG ,  CHEN WEI ,  JIA ZHAOZHONG J ,  LOURY DAVID J

    IPC: C07D403/14 ,  A61K31/519 ,  A61P19/00 ,  A61P19/02 ,  C07D401/14

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    PURINONE COMPOUNDS AS KINASE INHIBITORS
    24.
    发明专利
    PURINONE COMPOUNDS AS KINASE INHIBITORS 未知

    公开(公告)号：CA2917167A1

    公开(公告)日：2015-01-08

    申请号：CA2917167

    申请日：2014-06-30

    Applicant: PHARMACYCLICS LLC

    Inventor： CHEN WEI ,  JIA ZHAOZHONG J ,  LOURY DAVID J

    IPC: C07D473/34 ,  A61K31/52 ,  A61P19/02 ,  A61P37/00

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Patent Agency Ranking